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Abstract
OBJECTIVE: To study serum visfatin levels in wom-
en with polycystic ovary syndrome (PCOS) grouped
by Traditional Chinese Medicine (TCM) patterns.
To study the correlations of serum visfatin levels
with homeostatic model assessment insulin resis-
tance (HOMA-IR), fasting plasma glucose (FPG),
fasting insulin (FINS), body mass index (BMI), tes-
tosterone (T), total cholesterol (TC), and triglycer-
ides (TG).
METHODS: Two hundred and twelve PCOS pa-
tients were placed into the following TCM pattern
subgroups: Kidney-Yang deficiency (KYD) group,
Spleen-Yang deficiency (SYD) group, stagnant Liv-
er-Qi transforming into heat (SLQTH) group, and
Kidney-Yin deficiency (KYIND) group. The correla-
tions between serum visfatin levels and HOMA-IR,
FPG, FINS, BMI, T, TC, and TG were analyzed.
RESULTS: Of all patients with PCOS, there were 82
in the KYD group (38.6% ), 67 in the SYD group
(31.6%), 37 in the SLQTH group (17.5%), and 26 in
the KYIND group (12.3% ). Visfatin levels in all
PCOS subgroups were higher than those in the
control group (P<0.01 or P<0.05). Among these
subgroups, the visfatin levels in the SYD group
were significantly higher than those in the other
three TCM pattern groups (P<0.05). There were no
statistical differences among the remaining three
pattern groups. The levels of BMI, FINS, HOMA-IR,
T, and TG were significantly higher in all sub-
groups than those in the control group (P<0.05).
There were no significant differences in FPG and
TC between all PCOS subgroups and the control
group (P>0.05). The SYD group had higher levels
of FINS and HOMA-IR compared with the KYD,
SLQTH, and KYIND groups (P<0.05). In all sub-
groups, after controlling for BMI, TG, TC, and age,
visfatin was positively correlated with FINS (r=
0.197, P=0.015) and HOMA-IR (r=0.173, P=0.033),
and was not correlated with T.
CONCLUSION: KYD and SYD patterns are most
common in PCOS patients. Increased visfatin is a
common pathophysiologic manifestation in PCOS
patients. The SYD group had the highest levels of
visfatin, and visfatin was positively correlated with
FINS and HOMA-IR.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is a common repro-
ductive endocrine disorder. About 50% of PCOS pa-
tients have different levels of insulin resistance (IR).1
Traditional Chinese Medicine (TCM) has been used to
treat infertility for thousands of years. Recent studies
show that visfatin is associated with type 2 diabetes
mellitus, IR, PCOS, and other diseases.2-6 In this study,
we studied serum visfatin levels in women with differ-
ent TCM patterns and PCOS and their correlations
with homeostatic model assessment insulin resistance
(HOMA-IR), fasting plasma glucose (FPG), fasting in-
sulin (FINS), body mass index (BMI), testosterone
(T), total cholesterol (TC), and triglycerides (TG).
SUBJECTS ANDMETHODS
Patient inclusion and exclusion
The patient cohort included 212 women with PCOS
in the Reproductive Center of the First Affiliated Hos-
pital, Chongqing Medical University between June
2010 and April 2013. Diagnosis criteria for PCOS
were established by the Ministry of Health of the Peo-
ple's Republic of China.7 Women with PCOS were ex-
cluded if they took drugs within 6 months of the trial
that could possibly affect glycolipid metabolism, such
as corticosteroids, lipid-lowering drugs, anti-obesity
drugs, and anti-diabetic drugs. Patients were also ex-
cluded if they had acute inflammation. Patients were
grouped into four subgroups based on patterns differ-
entiated according to TCM theory. Thirty-six infertile
women served as the control group. All patients gave
informed consent and the trial was approved by the
Ethics Committee of The First Affiliated Hospital of
Chongqing Medical University.
Criteria of TCM pattern differentiation
TCM pattern differentiation criteria were established
in reference to the literature.8,9 The main symptoms of
Kidney-Yang deficiency (KYD) are oligomenorrhea
and amenorrhea. Minor symptoms include: aversion to
cold, loose stool, lassitude in the loin and legs, sexual
hypoesthesia, obesity, hair growth, and gonadal dysgen-
esis. The tongue-pulse diagnosis for KYD is plump
pale tongue with white fur, purplish dim tongue with a
whitish coating, or white and thin fur, and a sunken
and thin pulse. The main symptoms of Spleen-Yang de-
ficiency (SYD) include oligomenorrhea, menorrhagia,
or amenorrhea. Minor symptoms include: oppressed
feeling in the chest and nausea, anorexia, sallow com-
plexion, drowsiness, hypodynamia, obesity, hair
growth, and gonadal dysgenesis. The tongue-pulse diag-
nosis of SYD is plump pale tongue with white fur,
teeth-printed tongue, purplish dim tongue with whit-
ish coating, or white and thin fur, and a thin and slip-
pery pulse. The main symptoms of stagnant Liver-Qi
transforming into heat (SLQTH) are irregular menstru-
al period, oligomenorrhea, amenorrhea, or polyhyper-
menorrhea. Minor symptoms include: anxiety and irri-
tability; fullness in the chest, hypochondrium and
breast; galactorrhea; bitter taste in the mouth; furun-
cles; and postconnubial dysgenesia. The tongue-pulse
of gonadal dysgenesis include a red tongue with a thin
and yellow coating, and a thin and taut pulse. The
main symptoms of Kidney-Yin deficiency (KYIND)
are delayed menstrual cycle, oligomenorrhea, amenor-
rhea, or advanced menstrual cycle. Minor symptoms in-
clude: feverish sensation in the palms and soles, furun-
cles, dry mouth, coprostasis, obesity, hair growth, post-
connubial dysgenesia. The tongue-pulse diagnosis is a
red tongue with a thin coating, and a thin and rapid
pulse.
Measurement of circulating parameters
Patient FPG, FINS, T, TC, TG, height, and weight
were measured. Fasting plasma glucose (FPG) was mea-
sured immediately by the enzymatic method using an
Areoset analyzer (BS-200, Mindray, Shenzhen, China)
in hospital laboratory. The Fasting serum insulin
(FINS) and testosterone (T) were analyzed by the che-
miluminescent immunometric assay test method using
an Immulite analyzer (DXI-800, Beckman Coulter,
Brea, USA) in hospital laboratory. The serum total cho-
lesterol (TC) and triglycerides (TG) were assessed by
enzymatic methods (Modular DDP, Roche, Basel, Swit-
zerland) in hospital laboratory.
Visfatin levels were measured with an enzyme-linked
immunosorbent assay kit (Bio-Swamp, Shanghai, Chi-
na), following the manufacturer's instructions. The
minimum detectable concentration was 1 μg/L, the in-
tra-assay coefficient of variation was less than 9% , and
the inter-assay coefficient of variation was less than 15%.
The following formulas were used to calculate BMI
and HOMA-IR, respectively:
BMI=Weight (Kg)/(Height [m])2
HOMA-IR=(FPG[mmol/L]×FINS[mIU/L])/22.5.
Data analysis
SPSS 19.0 software (IBM, Chicago, IL, USA) was used
for data analysis. Quantitative data are expressed as
Mean±SD. The differences among groups were evaluat-
ed by one-way analysis of variance (non-parametric test
were used for heterogeneity of variance). Quantitative
data were compared using a Chi-square test. Correla-
tions between variables were assessed by Spearman's
correlation analysis and partial correlation analysis. P<
0.05 was considered significant.
RESULTS
Classified characteristics of TCM patterns in PCOS
patients
The cohort included 212 PCOS patients who had
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complete information and conformed to the diagnosis
criteria. The percentages of KYD, SYD, SLQTH, and
KYIND were: 38.6% (n=82), 31.6% (n=67), 17.5%
(n=37), and 12.3% (n=26), respectively (Table 1).
There was no significant difference in percentage be-
tween the KYD group and the SYD group (P>0.05).
However, the KYD and SYD groups had significantly
higher percentages than the SLQTH and KYIND
groups (P<0.05). In addition, no significant differences
in mean age or duration of infertility were observed be-
tween the PCOS group and the control group (P>0.05).
Comparison of the characteristics of four TCM
different pattern PCOS patients
The clinical and hormonal characteristics of different
TCM patterns of PCOS and the control group are
shown in Table 2. BMI, FINS, HOMA-IR, T, TG, and
visfatin were significantly higher in PCOS group than
those in the control group (P<0.01). There were no sta-
tistically significant differences in FPG and TC be-
tween the PCOS and control groups (P>0.05). The
SYD group had significantly higher levels of FINS, vis-
fatin, and HOMA-IR than those in the KYD,
SLQTH, and KYIND groups (P<0.05). There were no
significant differences in FINS, visfatin, and
HOMA-IR among the KYD, SLQTH, and KYIND
groups (KYD vs SLQTH, KYD vs KYIND, and
SLQTH vs KYIND, P>0.05). The serum level of tes-
tosterone in the KYIND group was significantly higher
than that in the KYD, SLQTH, and SYD groups (P<
0.05). No significant differences in testosterone were
found among the KYD, SLQTH, and SYD groups
(KYD vs SLQTH, KYD vs SYD, and SLQTH vs SYD,
P>0.05). Additionally, no statistically significant differ-
ences were observed in the levels of BMI, FPG, TG,
and TC among the four Chinese medical syndrome
groups.
Correlation analyses of clinical, biochemical, and
hormonal parameters in PCOS patients
The correlation analysis of clinical, biochemical, and
hormonal parameters in the PCOS group are shown
in Table 3. Visfatin is positively correlated with FINS
(r=0.171, P=0.013), HOMA-IR (r=0.185, P=0.007),
and T (r=0.148, P=0.047). There were no correla-
tions between visfatin and BMI, FPG, TC, or TG
(P>0.05). No correlations were observed between TG
and BMI, FINS, or HOMA-IR (P>0.05). TC did
not show any significant correlations with FINS and
HOMA-IR (P>0.05), and there were also no correla-
tions between T and BMI, FPG, FINS, HOMA-IR,
TG, or TC (P>0.05).
Notes: KYD: kidney-Yang deficiency group; SYD: spleen-Yang deficiency group; SLQTH: stagnant Liver-Qi transforming into heat group;
KYIND: kidney-Yin deficiency group; PCOS: polycystic ovary syndrome; TCM: Traditional Chinese Medicine.
Group
KYD
SYD
SLQTH PCOS
KYIND
Controls
n
82
67
37
26
36
Age (years)
28.3±3.9
29.2±5.2
27.1±3.1
26.8±2.7
29.2±2.7
Duration of infertility (years)
3.4±0.5
3.2±0.5
3.6±0.4
3.2±0.6
3.1±0.6
P value (%)
38.6
31.6
17.5
12.3
-
Table 1 Characteristics of TCM patterns in PCOS patients
Parameter
n
BMI (kg/m2)
T (ng/mL)
FPG (mmol/L)
FINS (mIU/L)
HOMA-IR
Visfatin (ng/mL)
TG (mmol/L)
TC (mmol/L)
KYD
82
24.63±3.09a
0.51±0.17ab
5.19±0.37
10.04±2.73ac
2.31±0.65ac
22.89±16.66ac
1.47±0.75a
4.43±0.94
SYD
67
25.57±3.29a
0.54±0.24ab
5.27±0.54
12.65±5.02a
3.00±1.36a
29.10±18.74a
1.64±1.12a
4.39±0.92
SLQTH PCOS
37
24.39±3.22a
0.52±0.21ab
5.19±0.35
10.02±2.18ac
2.32±0.51ac
18.93±18.79ad
1.31±0.49a
4.16±0.42
KYIND
27
24.64±2.95a
0.67±0.22a
5.18±0.35
9.98±3.24ac
2.31±0.79ac
19.32±18.01ad
1.30±0.51a
4.27±0.41
Controls
36
20.09±1.14
0.25±0.06
5.05±0.28
5.86±0.67
1.31±0.15
5.55±3.30
0.56±0.14
3.96±0.88
Table 2 Characteristics of four TCM pattern groups and control group ( xˉ ±s)
Notes: KYD: kidney-Yang deficiency group; SYD: spleen-Yang deficiency group; SLQTH: stagnant liver-Qi transforming into heat group;
KYIND: kidney-Yin deficiency group; TCM: Traditional Chinese Medicine; BMI: body mass index; T: testosterone; FPG: fasting plasma
glucose; FINS: fasting insulin; HOMA-IR: homeostatic model assessment insulin resistance; TG: triglycerides; TC: total cholesterol. aP<
0.01, for the difference between the PCOS and control groups; bP<0.05, for the difference between the KYIND, KYD, SYD, or SLQTH
groups; cP<0.05, dP<0.01 for the difference between the SYD and KYD groups, or the KYIND and SLQTH groups.
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Correlation analyses of clinical, biochemical, and
hormonal parameters in PCOS patients after
controlling for BMI, TG, TC, and age
The relationships between visfatin and clinical, bio-
chemical, and hormonal parameters in the PCOS
group after age, BMI, TG, and TC were controlled for
are shown in Table 4. Partial correlation analysis shows
that after controlling for BMI, TG, TC, and age, visfa-
tin still positively correlated with FINS (r=0.197, P=
0.015) and HOMA-IR (r=0.173, P=0.033). There was
no correlation between visfatin and T (P>0.05).
DISCUSSION
PCOS is an endocrine disorder syndrome characterized
by reproductive dysfunction and abnormal glucose me-
tabolism. Modern TCM theory hypothesizes that the
main mechanism of PCOS is the dysfunction of Kid-
ney, Liver, and Spleen, and generational and restriction-
al interrelationships among the Kidney-menstrua-
tion-Ren Chong-uterus imbalance. Consistent with
other reports,10-12 our data show that, in 212 patients
with PCOS, the proportions of KYD (38.6% ) and
SYD (31.6% ) were significantly higher than those of
SLQTH and KYIND (P<0.05). After analyzing the
syndrome differences among 120 patients with PCOS,10
we found that the KYD ratio was higher than other
patterns (P<0.05). Xiong et al 11 found that SYD had
the highest proportion (48%) in 105 PCOS patients,
followed by kidney deficiency (32% ). Therefore, we
considered KYD and SYD as the dominant TCM pat-
terns in patients with PCOS. Moreover, the pathogene-
sis of PCOS may be associated with Spleen-Yang and
Kidney-Yang deficiency and phlegm dampness.
Visfatin was first isolated from visceral adipose tissue of
human and mouse by Fukuhara et al 13 in 2005. Visfa-
tin can bind to the insulin receptor and phosphorylate
the tyrosine residues of the insulin receptor, insulin re-
ceptor substrate (IRS)-1, and IRS-2. This phosphoryla-
tion activates protein kinase B and the mitogen-activat-
ed protein kinase signaling pathway. Therefore, visfatin
shares the same signal transduction pathways as insu-
lin, and has similar hypoglycemic and other "insu-
lin-like" functions. However, the correlations between
visfatin and FINS and HOMA-IR are still controver-
sial.14-16 In the present study, we found that BMI,
FINS, HOMA-IR, and visfatin in PCOS patients were
higher than those in the control group (P<0.01). In-
creased serum visfatin in PCOS patients with abnor-
mal glucose tolerance may be a compensatory response
for insulin resistance by binding with insulin receptors
to increase insulin sensitivity. Abnormal glucose toler-
ance and insulin resistance may be the two causes of in-
creased serum visfatin. Correlation analysis showed
that, after controlling for the influence of BMI, TG,
TC, and age, visfatin was positively correlated with
FINS and HOMA-IR in the PCOS group. This indi-
cates that visfatin is positively correlated with insulin
resistance in PCOS patients and might reflect the ex-
tent of insulin resistance. Therefore, obesity may be an
abnormal visfatin condition, but obesity is not a deter-
minant of visfatin levels in PCOS patients.
In PCOS patients, abnormal lipid metabolism is close-
ly related to glucose metabolism. Similar to the obser-
vation by Tarkun et al,17 we found that TG in PCOS
patients was higher than that in the control group (P<
0.05). There were no differences in TC between the
PCOS and control groups. Another study showed that
insulin reduced the expression of adipose triglyceride li-
pase (ATGL) in 3T3-L1 cells, and ATGL expression in
a diabetes-obesity mouse model (ob/ob, db/db) de-
creased by 50% .18 This suggested that ATGL expres-
sion decreases during IR. However, the main function
Parameter
BMI
FPG
FINS
HOMA-IR
T
TG
TC
Visfatin
r
0.125
0.061
0.171
0.185
0.148
﹣0.047
﹣0.124
P value
0.069
0.375
0.013
0.007
0.047
0.492
0.071
T
r
0.042
0.069
0.015
0.033
-
0.014
0.180
P value
0.576
0.335
0.839
0.660
-
0.857
0.016
BMI
r
-
0.072
0.085
0.117
0.042
0.039
0.030
P value
-
0.295
0.218
0.089
0.576
0.569
0.667
TG
r
0.039
-
0.079
﹣0.109
0.014
-
0.305
P value
0.569
-
0.253
0.112
0.857
-
0.000
TC
r
0.030
﹣0.040
0.001
﹣0.021
0.180
0.305
-
P value
0.667
0.733
0.997
0.765
0.016
0.000
-
Table 3 Relationships between clinical, biochemical, and hormonal parameters
Notes: BMI: body mass index; FPG: fasting plasma glucose; FINS: fasting insulin; HOMA-IR: homeostatic model assessment insulin resis-
tance; T: testosterone; TG: triglycerides; TC: total cholesterol.
Statistical
Parameter
r
P value
FPG
﹣0.021
0.8
FINS
0.197
0.015
HOMA-IR
0.173
0.033
T
0.142
0.081
Table 4 Relationships between clinical, biochemical and hor-
monal parameters in all PCOS patients after controlling for
BMI, TG, TC, and age
Notes: FPG: fasting plasma glucose; FINS: fasting insulin;
HOMA-IR: homeostatic model assessment insulin resistance; T:
testosterone. BMI: body mass index; TG: triglycerides; TC: total
cholesterol.
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of ATGL, the key enzyme of lipid metabolism, is to cat-
alyze TG by hydrolyzing it into diglycerides and FFA.
In this case, IR decreases TG hydrolysis, resulting in in-
creased TG. Other researchers found that TG and TC
in the IR group were higher than those in the non-IR
group, and TG and TC were positively correlated with
HOMA-IR.19 However, the results of our study showed
that TG was not correlated with FPG, FINS, or
HOMA-IR. Therefore, IR may be the main reason for
elevated TG in vivo, and may play a role in the occur-
rence of dyslipidemia in PCOS patients. In contrast to
TG, visfatin could more effectively reflect the state of
insulin resistance in PCOS women.
Hyperandrogenism is considered to be the main endo-
crine characteristic of PCOS patients. Previous studies
found that insulin could increase the synthesis of an-
drogen,20,21 and visfatin was positively correlated with
T in patients with PCOS.2,14 In the present study, T
levels were significantly higher in PCOS patients
than those in the control group (P<0.01). T was pos-
itively correlated with visfatin, but not FINS or
HOMA-IR. Consistent with others,5,22-24 there were
no correlations between T and FINS or HOMA-IR
after controlling for BMI. Therefore, we believe that
visfatin was not correlated with T, and had no direct
links with synthesis, secretion, and metabolism of sex
hormones.
In the present study, the BMI, FINS, HOMA-IR, and
serum visfatin levels of PCOS patients with four differ-
ent TCM syndromes were higher than those in the con-
trol group (P<0.01). The levels of visfatin, FINS, and
HOMA-IR in the SYD group were higher than those
in the other three groups (P<0.05). Elevated serum vis-
fatin level is a common pathological manifestation in
PCOS with different TCM syndromes, especially in
SYD patients. According to TCM theory, because of
spleen-Yang deficiency, the dysfunction of transforma-
tion and transportation, and the stasis of body fluids
and food essence in the meridians and collaterals, the
muscular interstitial space cannot be used by the body
and there is stagnation of phlegm, which will eventual-
ly lead to obesity. The increase in adipose tissue is the
most important reason for increased FINS and
HOMA-IR. Our previous study retrospectively ana-
lyzed 510 patients with PCOS and found that IR in
the SYD group is higher than those in the other three
groups (P<0.01).25 Based on these results, the main
pathological manifestations of SYD PCOS patients are
glucose and lipid metabolism disorders. The spleen is
the main organ involved in metabolism, especially in
glucose and lipid metabolism. Therefore, the transpor-
tation dysfunction of the spleen may be similar to the
pathological mechanisms of insulin resistance in West-
ern Medicine.
In conclusion, the patterns of KYD and SYD were
most common in patients suffering from PCOS. The
levels of visfatin were significantly higher in the PCOS
group than those in the control group. FINS, HOMA-
IR, and visfatin levels were highest in the SYD group.
Visfatin was positively correlated with FINS and
HOMA-IR, and it could more effectively reflect the in-
sulin resistance situation of PCOS patients than T or
TG. Therefore, visfatin may be an indicator for the
management of PCOS.
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